Analyst William Pickering of Bernstein maintained a Hold rating on Ionis Pharmaceuticals, with a price target of $42.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
William Pickering’s rating is based on a combination of factors including Ionis Pharmaceuticals’ recent strong quarterly performance and future growth expectations. The company exceeded revenue and earnings estimates significantly, and their revenue guidance for the fiscal year 2025 was raised. However, despite the impressive performance, management has indicated that growth may slow as the focus shifts to finding new patients for their drug Tryngolza.
Additionally, while there is optimism surrounding the upcoming launch of donidalorsen for hereditary angioedema, there are uncertainties regarding the potential outcomes of their sHTG Phase 3 trial. The stock has already seen a substantial increase, which suggests that positive outcomes may already be priced in, leading to potential downside if expectations are not met. These factors contribute to the Hold rating, reflecting a balanced view of the risks and opportunities facing Ionis Pharmaceuticals.
According to TipRanks, Pickering is an analyst with an average return of -2.5% and a 52.46% success rate. Pickering covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Regeneron, and Ionis Pharmaceuticals.
In another report released on July 17, BMO Capital also maintained a Hold rating on the stock with a $40.00 price target.